Company / Shareholders' Equity
Lineage Cell Therapeutics, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$44.5M
FY2025
5-year range
$44.5M / $92.2M
FY2021-FY2025
Trend
-43.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 10 years, ranging from $45M in FY2025 to $163M in FY2017.
Based on SEC 10-K filings.
$45M in FY2025 with a 5-year CAGR of -14.3%.
Declined from $63M to $45M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -15.3%
- 5-Year CAGR
- -14.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -14.3%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 43.2% year-over-year.
- Peak shareholders' equity was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.5M | -43.2% |
| FY2024 | $78.4M | +23.6% |
| FY2023 | $63.4M | -13.5% |
| FY2022 | $73.3M | -20.5% |
| FY2021 | $92.2M | -4.1% |
| FY2020 | $96.2M | +2.5% |
| FY2019 | $93.8M | +0.0% |
| FY2018 | $93.8M | -42.3% |
| FY2017 | $162.6M | +37.9% |
| FY2016 | $117.9M | +338.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026